Abstract CT062: Single institution experience of the phase 1 expansion study of IK-595, a novel MEK-RAF molecular glue, in patients with NRAS/KRAS mutated advanced tumors

作者
Jennifer Brooke Valerin,Connie Kang,Christine Choe,Trupti Lingaraj,Farshid Dayyani
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (8_Supplement): CT062-CT062
标识
DOI:10.1158/1538-7445.am2026-ct062
摘要

Abstract Background: Alterations in the RAS/RAF/MEK/ERK pathway are the most common drivers of oncogenesis. IK-595 is a novel MEK-RAF molecular glue designed to overcome resistance mechanisms by stabilizing MEK and all RAF isoforms in an inactive conformation. Anti-tumor activity was observed in KRAS-driven models when IK-595 was given alone and improved responses were seen when added to standard chemotherapy. Methods: Patients (pts) with metastatic RAS-mutant pancreatic adenocarcinoma (mPDAC) received Gemcitabine/nab-paclitaxel (1000/125 mg/m2 i.v. weekly for 3 of 4 weeks in 28-day cycle) plus escalating doses of IK-595 p.o. (combo) as 1L or IK-595 (4mg twice p.o. weekly for 28 days) alone (mono) for 2L. Metastatic colorectal cancer (mCRC) with NRAS mutation was enrolled in dose escalation at 6mg twice weekly p.o. for 28 days. Primary objective was safety and tolerability. Secondary objective was antitumor activity. Here we describe our institution’s experience. Results: At all participating sites, 51 total patients enrolled in monotherapy dose escalation, 5 in combo escalation and 19 with KRAS G12R mutation only in monotherapy expansion (4 mg twice weekly). 12 pts were treated at our institution, 7/12 in expansion monotherapy arm (1 prior line of treatment) and 4/12 with the combo (treatment-naïve). Objective response rate was 25% with mono and 50% with combo, including 1 complete response; disease control rate was 88% and 75%, respectively, and the responses were sustained for over 6 months in all responders. CA 19-9 responses (≥20% decline in CA 19-9) were observed in 80% in mono and 100% in combo for those evaluable. Of note, 1 pt with NRAS mutant-mCRC, after with 2 prior lines, is still on study (on dose escalation) with on-going PR after 8 cycles. Treatment-related adverse events (TRAE, ≥ 15%) in the monotherapy arm were mostly mild, with rash (100%) being the most common, followed by diarrhea (57%), fatigue (43%), nausea/vomiting (28%), and ocular changes (28%). Grade 3 TRAE of elevated LFTs occurred in one mono pt and G3 elevated troponin in one combo pt. No Grade 4/5 TRAEs occurred. Conclusions: IK-595 showed an acceptable safety profile and compelling efficacy in both treatment-naïve mPDAC pts with KRAS mutation in combination with chemotherapy as well as 2L mPDAC and mCRC RAS mutant pts. These data support further treatment of this patient population with this novel agent. Citation Format: Jennifer Brooke Valerin, April Choi, Connie Kang, Miranda Duron, Christine Choe, Katherine Kim, Trupti Lingaraj, David Damphousse, Farshid Dayyani. Single institution experience of the phase 1 expansion study of IK-595, a novel MEK-RAF molecular glue, in patients with NRAS/KRAS mutated advanced tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr CT062.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
幽默兰完成签到,获得积分10
刚刚
PL发布了新的文献求助10
刚刚
打打的应助被INT采纳,获得10
1秒前
李健的应助被Jio-PPx采纳,获得10
1秒前
你相信光吗完成签到 ,获得积分10
1秒前
2秒前
2秒前
suxian完成签到,获得积分10
3秒前
shadow完成签到,获得积分10
4秒前
文献互助发布了新的文献求助10
4秒前
十四发布了新的文献求助10
4秒前
5秒前
5秒前
yancy76完成签到,获得积分10
5秒前
5秒前
6秒前
6秒前
没假期完成签到 ,获得积分10
6秒前
lilac发布了新的文献求助10
7秒前
7秒前
link完成签到 ,获得积分10
8秒前
小马甲的应助被serein采纳,获得10
8秒前
充电宝的应助被zqy采纳,获得10
9秒前
SciGPT的应助被gqz采纳,获得10
9秒前
神勇秋蝶发布了新的文献求助10
9秒前
10秒前
fx发布了新的文献求助10
10秒前
10秒前
10秒前
时思发布了新的文献求助10
10秒前
Ava的应助被rururu采纳,获得10
10秒前
NexusExplorer的应助被彩色鸿涛采纳,获得10
10秒前
12秒前
12秒前
孙浩文发布了新的文献求助10
12秒前
QQ发布了新的文献求助10
13秒前
Huaaaaay完成签到,获得积分10
13秒前
13秒前
勒言完成签到,获得积分10
13秒前
张张的应助被含糊的静芙采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239